

SKINOPATHY

Skinopathy provides healthcare practitioners and patients real-time solutions on how to screen, triage, track, and manage skin cancers, skin diseases, and skin wounds through artificial intelligence, advanced data analytics, and automation.

The Problem

Skinopathy was started during the pandemic when our Co-Founder, Dr. Colin Hong, noticed patients were coming to his clinic presenting with late-stage skin cancer due to delayed and/or canceled skin cancer screenings.

Not only were people's well-being at stake, but he knew that these delays would only get worse and stretch an already taxed healthcare system to its limits.

That is when he decided to collaborate with technologist and entrepreneur, Keith Loo, MBA, to revolutionize, digitize, and automate the entire dermatological journey. Everything from screening to research.

Core Products & Services

SkinAI™

Patent-pending dermatological AI that can be used on any cellphone camera for screening skin cancers, identifying and measuring psoriasis and dermatitis, tracking the healing process of wounds, and much more.

GetSkinHelp™

Telemedicine platform that connects individuals, doctors, and the complete patient circle-of-care to the SkinopathyOS suite of products and services.

SkinopathyOS™

Data-first medical operating system that powers the full suite of Skinopathy products and services and provides physicians unprecedented intelligence about their practice.

Achievements & Recognitions

- Awarded First Prize for Innovation at the Canadian Society of Plastic Surgery Conference
- Won the AIMed Conference Abstract Competition for originality, scholarship, and potential impact.
- Won international INSEAD Business for Good award.
- Won 2nd place at the LG Nova Startup Competition in Silicon Valley and chosen as 1 of 40 startups in a field of over 2,200 to join them on their Mission for the Future.
- Nominated by the Responsible AI Institute for Lead AI startup of the Year in New York City.
- Published Study Abstract in Journal of Burn Care and Research
- Published manuscript in MedRxiv pre-print server
- Presented at Canadian Burns Association, Canadian Society of Plastic Surgeons & American Burns Association
- Presented and featured for Innovation in Cosmetics at the Cosmetics Alliance of Canada

The Results

Since incorporation in August 2020, over 400 doctors have chosen to send us more than 15,000 patients and are now working alongside government agencies, like the National Research Council, Global Affairs Canada, and Innovation Canada to make Skinopathy a staple in dermatology.

Over the last year, large hospital networks, wound care product companies, technology manufacturers, cosmeceuticals/pharmaceuticals, and long-term care operators are all at our door hoping to integrate our technology in their operations.

All to say, the future looks bright for Skinopathy!

Regulatory

- Class I Medical Device Active License Listing (MDALL) designation with Health Canada.
- Active Medical Devices Establish License (MDEL) with Health Canada.
- SkinAI technology exceeds incoming FDA AI accuracy regulations.
- Contracted with U.S. biotechnology compliance agency for FDA listing.